The abnormally activated PI3K/AKT pathway is less likely to respond to the use of chemotherapy agents, such as paclitaxel and trastuzumab, at both the preclinical and clinical stages of breast cancer similar to the LGSOCs [20,21]. This evidence concerns the gene PIK3CA and breast carcinoma.